Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369417 · ClinicalTrials.gov registry record · NA
Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD)
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT04369417: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04369417 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04369417, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The proposed research has the following objectives: Based off findings from the "Development of a Resiliency Program for Siblings of Children with Autism Spectrum Disorder" qualitative focus group study (protocol 2019P002284), the aim is to determine the feasibility and acceptability, of an 8-session Relaxation Response Resiliency (SibChat) program for siblings of children with ASD. We primarily aim to test the preliminary effectiveness of a pilot waitlist controlled trial on improving resiliency and stress coping, This will be assessed by comparing Baseline-3 mo. scores on primary and secondary outcome measures between the Immediate and Waitlist control groups. Among participants randomized to both conditions, we secondarily aim to investigate the extent of pre-post changes in primary and secondary outcomes. Among immediate condition group only, we also aim to assess whether end-of-treatment (3 mo. post enrollment) improvements will be sustained at 6-mo. post enrollment.
Interventions
- BEHAVIORAL Relaxation Response Resiliency Program for Siblings of Children with ASD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2021-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369417
The ClinicalTrials.gov registry entry for NCT04369417 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Relaxation Response Resiliency Program for Siblings of Children with ASD is the first listed.
NCT04369417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04369417 about?
NCT04369417 is a clinical study titled "Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD)". The proposed research has the following objectives: Based off findings from the "Development of a Resiliency Program for Siblings of Children with Autism Spectrum Disorder" qualitative focus group study (protocol 2019P002284), the aim is to determine the feasibility and acceptability, of an 8-sessi...
What is the current status of trial NCT04369417?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2020-01-28. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT04369417?
The interventions under investigation include: Relaxation Response Resiliency Program for Siblings of Children with ASD (BEHAVIORAL).
Who is sponsoring clinical trial NCT04369417?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.